ADPKD: the most common hereditary kidney disease — the AU GP guide

What ADPKD is

Autosomal dominant polycystic kidney disease (ADPKD) is the most common inherited single-gene kidney disease, affecting approximately 1 in 1,000 Australians — around 25,000 people nationally (KHA-CARI Australasian ADPKD guideline). Fluid-filled cysts form and enlarge progressively in both kidneys over decades, crowding out normal kidney tissue and progressively impairing function.

The condition is caused by mutations in either the PKD1 gene (around 80% of cases) or the PKD2 gene (around 15–20%). Both genes encode proteins — polycystins — critical for normal kidney tubule development. When these proteins are faulty, tubule cells form fluid-filled cysts that expand driven by a specific hormonal signalling pathway involving vasopressin and cyclic AMP. PKD1 mutations generally cause faster progression, with median age at kidney failure around 58 years, compared with around 79 years for PKD2 (KDIGO ADPKD Controversies Conference 2024).

Because the condition is autosomal dominant, each child of an affected parent has a 50% chance of inheriting it. About 10% of cases arise without a family history, due to new mutations.

The condition also affects structures outside the kidneys. Hepatic cysts develop in around 80% of people and are usually asymptomatic, though they can become massive and symptomatic in some women, especially with a history of oestrogen exposure. A small but clinically relevant increased risk of brain aneurysms exists — around 5–10% prevalence, roughly five times the general population. Mitral valve prolapse, abdominal hernias, and diverticular disease are also associated.

ADPKD accounts for approximately 5–10% of all Australians receiving kidney replacement therapy, according to the ANZDATA Registry.

A. Core clinical — the AU general-practice framework

The progression story

ADPKD follows a predictable, decades-long trajectory. Hypertension is typically the first clinical sign, often appearing before age 30 — well before any measurable decline in eGFR (eTG Nephrology). This occurs because expanding cysts compress surrounding blood vessels, activating the intra-renal renin–angiotensin system even when overall kidney function appears normal on blood tests.

Kidney function often remains compensated into the fourth or fifth decade as intact nephrons work harder to cover for those lost to cyst expansion. Once compensation is exhausted, eGFR declines — often at 3–5 mL/min/1.73m² per year in rapid progressors. Around 50% of people with PKD1 mutations develop end-stage kidney disease (ESKD) by age 60.

GP assessment

Structured review of new or established ADPKD covers:

• Blood pressure — measure at every visit; target below 130/80 mmHg for most adults (HALT-PKD-A, NEJM 2014). In younger adults aged 15–49 with preserved eGFR and rapid progression, a target below 110/75 mmHg may offer additional kidney-volume benefits — individualise and avoid in older or frailer patients.
• Kidney function — UEC + eGFR, and urine albumin-to-creatinine ratio, at least annually in stable CKD 1–2, every 3–6 months as CKD advances.
• Haematuria — most episodes (from cyst rupture) are macroscopic, painful, and settle with rest and hydration within days. Persistent or atypical haematuria requires urological investigation to exclude a coincident renal cancer.
• Flank or abdominal pain — characterise as acute (cyst haemorrhage, infection, or stone) versus chronic (mechanical from organ enlargement).
• Medication review — remove NSAIDs entirely from the medication list; check for nephrotoxic herbal preparations, high-dose vitamin C, and ACEi–ARB combination therapy (the latter carries increased AKI and hyperkalaemia risk without benefit).

Initial investigations

At diagnosis or when ADPKD is first identified, arrange:

• UEC + eGFR (MBS 66500) — baseline, then 6–12-monthly; every 3–6 months once eGFR falls below 60.
• Urine albumin-to-creatinine ratio (MBS 73529) — proteinuria in ADPKD is usually modest; nephrotic-range proteinuria raises concern for a coincident glomerular condition.
• Renal ultrasound — the primary diagnostic tool, interpreted using age-adjusted Pei–Ravine criteria for at-risk relatives: three or more cysts (unilateral or bilateral) age 15–39 years; at least two cysts in each kidney age 40–59; four or more in each kidney age 60 and over. A normal ultrasound (fewer than two total cysts) at or after age 40 effectively excludes ADPKD with over 99% negative predictive value.
• Liver function tests (LFTs) — baseline, and mandatory monthly for the first 18 months on tolvaptan.
• Lipids and HbA1c — cardiovascular risk assessment per the Heart Foundation 2023 CVD guideline.
• FBC — anaemia of chronic kidney disease when eGFR falls below 60.

Blood pressure management

ACE inhibitors or ARBs are first-line antihypertensives in ADPKD. The HALT-PKD trials confirmed their superiority for both blood pressure control and slowing kidney volume growth compared with non-RAAS agents. Common choices per AMH: ramipril 2.5–10 mg daily, perindopril 4–8 mg daily, or irbesartan 150–300 mg daily. The ACEi + ARB combination must be avoided — it increases acute kidney injury and hyperkalaemia risk without added benefit.

B. Evidence: tolvaptan and disease progression

What the trials showed

Tolvaptan (Jinarc) is a vasopressin V2-receptor antagonist that directly targets the cAMP pathway driving cyst expansion. Two pivotal randomised trials established its role.

The TEMPO 3:4 trial (Torres, NEJM 2012) enrolled 1,445 adults with CKD stages 1–3 and randomised them to tolvaptan or placebo for three years. Kidney volume growth was halved in the tolvaptan group (2.8% vs 5.5% per year) and eGFR decline slowed by approximately 1 mL/min/1.73m² per year.

The REPRISE trial (Torres, NEJM 2017) extended these findings to adults with eGFR 25–65, confirming preserved benefit at more advanced kidney disease.

Modelling estimates tolvaptan may delay ESKD by 4–6 years over a lifetime in eligible rapid progressors — a meaningful delay for transplant planning and quality of life, though the aquaresis burden limits real-world tolerability.

Who qualifies for PBS-subsidised tolvaptan

Tolvaptan is listed on the PBS as a Section 100 Highly Specialised Drug with strict eligibility criteria — nephrologist initiation is mandatory; GPs cannot initiate the prescription:

• Aged 18–50 at initiation
• eGFR ≥30 mL/min/1.73m²
• Mayo Imaging Class 1C, 1D, or 1E (confirmed on MRI or CT using height-adjusted total kidney volume)
• Not pregnant or breastfeeding; effective contraception in place

Without PBS subsidy, tolvaptan costs approximately A$40,000 per year. PBS listing has been in place since 1 April 2018.

Side effects to counsel on

The defining side effect of tolvaptan is aquaresis — a pronounced fluid output of 5–7 litres of urine per day as a direct consequence of its mechanism. Thirst, nocturia, and frequent voiding require practical planning: keeping water at the bedside, scheduling nocturia, hydrating consistently through the day.

Liver enzyme elevation occurs in 4–5% of people on tolvaptan; rarely, serious liver injury has been reported. Monthly LFT monitoring is mandatory for the first 18 months on tolvaptan, then three-monthly indefinitely. If LFTs rise significantly, tolvaptan should be withheld and nephrology contacted urgently. Approximately 20–25% of people discontinue tolvaptan due to the aquaresis burden.

Hydration as a standalone strategy

High water intake (targeting 2.5–3 litres per day) was widely recommended for ADPKD based on the same vasopressin-suppression rationale as tolvaptan. However, the PREVENT-ADPKD trial (Rangan, Lancet Regional Health 2022) — a pragmatic Australian randomised controlled trial — showed no slowing of kidney volume growth at three years with coached high fluid intake. Adequate hydration can be encouraged as a reasonable general measure, without being presented as proven disease-modifying therapy.

C. Complications: recognition and management

Cyst haemorrhage

Blood in the urine, or loin pain with or without visible haematuria, often signals a cyst that has bled internally or ruptured into the collecting system. Most episodes resolve with rest, adequate fluid intake, and paracetamol within 2–7 days. Heavy ongoing haematuria may need hospital admission; transfusion and radiological embolisation are rarely required. NSAIDs must not be used to manage this pain — they increase bleeding risk and can acutely worsen kidney function.

Cyst infection

Fever with flank pain and a tender enlarged kidney suggests cyst infection — a serious complication because many antibiotics penetrate cyst fluid poorly. eTG Nephrology recommends lipid-soluble antibiotics that achieve intracystic concentrations: ciprofloxacin 500 mg twice daily or trimethoprim–sulfamethoxazole, continued for 2–6 weeks depending on clinical response. Urine cultures are often negative. CT, MRI, or FDG-PET scanning may help confirm the diagnosis. Hospitalisation is warranted if the patient appears septic or cannot tolerate oral therapy.

Kidney stones

Around 20–25% of people with ADPKD develop kidney stones — predominantly uric acid stones (due to low urinary pH and a urine concentration defect) and calcium oxalate stones. Management follows standard protocols, with urinary alkalinisation using potassium citrate preferred for uric acid stones to maintain urine pH above 6.

Brain aneurysm screening

The prevalence of intracranial aneurysm (ICA) in ADPKD is 5–10%, roughly five times the general population. However, routine MRI angiography screening for all people with ADPKD is not recommended — most aneurysms are small and low-risk, intervention carries its own morbidity, and unselective screening generates anxiety without proven clinical benefit (KHA-CARI ADPKD guideline).

Selective MRA brain is appropriate when:

• A family member has had a brain aneurysm or subarachnoid haemorrhage
• The person has had a prior ICA
• High-risk occupation (commercial pilot, diver)
• Major planned surgery requiring anticoagulation or with substantial haemodynamic stress

D. Australian operations

MBS items

GPs managing ADPKD can use:

• Level C or D consultations (MBS 36/44) — appropriate for multi-system ADPKD review.
• GP Chronic Condition Management Plan (GPCCMP) — MBS 965 (preparation) and 967 (review) — ADPKD qualifies as a complex chronic condition requiring multidisciplinary care, replacing the former GPMP/TCA items.
• Allied health under GPCCMP — dietitian (MBS 10954) for low-sodium diet and weight management; exercise physiology (10953) for structured exercise; psychology (10968) for psycho-renal support and adjustment to a genetic diagnosis.
• Mental Health Treatment Plan (MBS 2715) — for anxiety around genetic diagnosis, tolvaptan aquaresis, or ESKD trajectory.
• Telehealth — video item 91890 or phone 92029 after 12-month established relationship. Well-suited to blood pressure monitoring, tolvaptan adherence support, and scan result discussions.

Genetic testing and insurance

Genetic testing for PKD1/PKD2 is not required for diagnosis in typical familial ADPKD — clinical and ultrasound criteria suffice. Testing is indicated for atypical presentations, sporadic cases (no family history), living donor evaluation in at-risk relatives, and reproductive counselling including pre-implantation genetic testing. Access in Australia typically involves self-funded testing at approximately A$1,500–2,500 through accredited laboratories; Medicare does not rebate ADPKD genetic testing outside specific specialist pathways.

Insurance implications are significant. Under the FSC Standard No. 11 moratorium framework, unfavourable genetic results do not need to be disclosed for life insurance policies up to specified caps. Pre-test genetic counselling should cover this explicitly, so patients can make an informed decision about proceeding.

Referral pathway

Situation	Who to refer	Urgency
New ADPKD diagnosis	Nephrology	Routine (within 3 months)
At-risk relative ≥18 wanting screening	Renal ultrasound ± nephrology	Routine
Cascade family testing / genetic counselling	Clinical genetics / Family Cancer Clinic	Routine
Reproductive planning / pre-implantation	Clinical genetics + IVF specialist	Routine
Living donor evaluation from at-risk relative	Renal transplant unit + genetics	Soon
Suspected cyst infection — septic	Nephrology and/or ED	Urgent
Persistent or atypical haematuria	Urology + imaging	Soon
BP uncontrolled or suspected renovascular cause	Nephrology	Soon
Family history of brain aneurysm	MRA brain ± neurosurgery	Routine–soon
eGFR below 25 or rapidly declining	Renal transplant unit	Soon
Mayo 1C/1D/1E candidate for tolvaptan, aged 18–50	Nephrology	Routine

E. Special populations

Pregnancy. Women with ADPKD generally tolerate pregnancy well when blood pressure is controlled and eGFR is preserved, but pregnancy accelerates hepatic cyst burden, particularly with multiple pregnancies. ACE inhibitors and ARBs are contraindicated in pregnancy — switch to methyldopa, labetalol, or nifedipine under obstetric or renal guidance, ideally before conception. Tolvaptan is contraindicated in pregnancy.

Children and adolescents. Pre-symptomatic ultrasound testing for at-risk children under 18 is generally deferred in the absence of symptoms, since diagnosis has no curative implication at that age and may affect future insurance. Blood pressure measurement at every clinical encounter is appropriate for known at-risk children and adolescents. Tolvaptan is not PBS-subsidised under 18, and evidence for benefit at early-adolescent stages is limited.

Older adults. As CKD advances from ADPKD, coincident drug management becomes more complex. Antihypertensives need dose adjustment as eGFR falls; NSAIDs — even occasional self-purchased ones — carry heightened AKI risk. Advance care planning conversations — dialysis versus a conservative pathway, transplant eligibility — should begin when eGFR reaches 30 and be well-established before eGFR falls below 15. Advance Care Planning Australia provides frameworks and documentation for this discussion.

Aboriginal and Torres Strait Islander Australians. Higher background rates of end-stage kidney disease from all causes mean ADPKD may accelerate an already increased burden. The ATSI Health Assessment (MBS 715) provides an annual opportunity to systematically monitor blood pressure, kidney function, and cardiovascular risk in this population.

Women and polycystic liver disease. Hepatic cysts grow faster in women with more oestrogen exposure (contraceptive pill, hormone replacement therapy, multiple pregnancies). Women with already large polycystic liver disease should discuss non-oestrogen contraception and HRT alternatives with their specialist team.

When to escalate

Refer urgently (same day or emergency) when:

• Fever with flank pain and systemic features of sepsis — suspect cyst infection
• Sudden severe headache unlike any previous, especially with neck stiffness — exclude subarachnoid haemorrhage
• Heavy haematuria that is not settling or causing haemodynamic instability
• Hypertensive emergency (BP ≥180/120 mmHg with end-organ symptoms)
• Significant LFT rise on tolvaptan — withhold the dose and contact nephrology immediately

Refer routinely:

• All newly diagnosed ADPKD → nephrology for risk stratification (Mayo classification, tolvaptan eligibility, BP guidance)
• At-risk relatives ≥18 wanting screening → renal ultrasound + nephrology if positive
• Candidates for tolvaptan → nephrology (nephrologist initiates and manages; GP co-monitors LFTs)
• Reproductive counselling or living donor evaluation → clinical genetics and transplant unit

What this article is and is not

This is general health information drawn from current Australian general practice and nephrology guidelines, including KHA-CARI ADPKD guidelines, eTG Nephrology, AMH, and published trial evidence. It is not personal medical advice and does not create a doctor–patient relationship. Decisions about diagnosis, medication, tolvaptan eligibility, and genetic testing are made with your GP and specialist team.

Consumer resources: PKD Australia, Kidney Health Australia, HealthDirect — Polycystic kidney disease.

For crisis support: Lifeline 13 11 14, Beyond Blue 1300 22 4636.

---

Sources cited

1. KHA-CARI — ADPKD Australasian guideline
2. Therapeutic Guidelines (eTG) — Nephrology: ADPKD
3. RACGP — Chronic kidney disease management in general practice
4. Australian Medicines Handbook
5. KDIGO ADPKD Controversies Conference 2024
6. Heart Foundation — Australian CVD risk guideline 2023
7. PKD Australia
8. Kidney Health Australia
9. HealthDirect — Polycystic kidney disease
10. PBS — Jinarc (tolvaptan) Section 100 listing
11. Torres VE et al. — TEMPO 3:4 (NEJM 2012)
12. Torres VE et al. — REPRISE (NEJM 2017)
13. Schrier RW et al. — HALT-PKD-A (NEJM 2014)
14. Rangan GK et al. — PREVENT-ADPKD (Lancet Reg Health 2022)
15. Irazabal MV et al. — Mayo Imaging Classification (JASN 2015)
16. Australian Immunisation Handbook
17. Advance Care Planning Australia
18. ANZDATA Registry
19. FSC Standard No. 11 — Genetic test results in life insurance